Homepage > Company > Media > Pharma News > 2018 > Past and present of imaging modalities used for prostate cancer diagnosis

Past and present of imaging modalities used for prostate cancer diagnosis

Prostate cancer is the second prevent type of cancer that exists. Prostate cancer is usually a slowly progressing disease but it can sometimes manifest as an aggressive cancer. Prostate imaging is the primary way to diagnose the disease and this necessity drives its demand in the clinic.

This review covers traditional and new imaging methods for screening the prostate gland for the occurrence of neoplasms. A special focus is given to Prostate Specific Membrane Antigen (PSMA), Bombesin (BN) and Androgen Receptor (AR) targeted imaging using Positron Emission Tomography (PET) and Single Positron Emission Computed Tomography (SPECT) based on 99mTc and other radiotracers.

The reviewers conclude that androgen receptor based imaging is the future direction for prostate specific imaging and can be a better way to diagnose prostate cancer using non-steroidal antiandrogen agents.

24-DEC-2018

https://www.eurekalert.org/

Read also

FDA warns vs fake versions of popular medicines

MANILA, Philippines - counterfeit versions of some popular over-the-counter pain relievers and flu medicines are circulating in the market, the Food and Drug Administration (FDA) reported. ...

Japan's Eisai inks $2 B oncology deal with China-based startup Bliss Biopharma

Cognixion, a developer of non-invasive Brain-Computer Interface (BCI) and Augmented Reality (AR) technology, has announced that the US Food and Drug Administration (FDA) has granted its device Brea...

Cognixion receives FDA Breakthrough Device Designation for assisted communication device

EMA to review CTIS transparency rules

Public consultation seeks the best methods for balancing transparency with confidentiality in the EU Clinical Trials Information System, says the European Medicines Agency. ...